In English
NIDA

Investigaciones sobre los tratamientos

Dr. Kevin M. Gray Q & A: A Potential Medication for Marijuana Dependence

Dr. Kevin M. Gray discusses why it’s the perfect time for discovering new evidence-based treatments for marijuana dependence. In an accompanying podcast, he discusses a clinical trial that examines NAC’s potential as a treatment for marijuana dependence among adults.

New Approach Uses Immune Cells To Deliver Anti-HIV Medications

Nano-antiretroviral therapy (nano-ART) turns macrophages—one of the very cell types that HIV uses to replicate and spread through the body—into carriers for anti-HIV medications. The approach has the potential to make treatment for HIV easier and more effective.

Training Workshops Boost Approval of Contingency Management

Clinicians associated with the Veterans Administration looked more favorably upon contingency management after attending training workshops on the use of the intervention. Despite being highly effective at decreasing drug use, contingency management is one of the least used among proven substance abuse treatments.

New brain imaging dataset now available to enhance reliability and reproducibility

A new NIDA-supported dataset will now allow researchers to compare their MRI-based scans against more than 10,000 brain images, thereby enhancing reliability and reproducibility.


Gene Variants Reduce Opioid Risks

Two recent studies suggest that genotyping may enable clinicians to base therapies on individual patients’ potential responsiveness to opioid drugs’ therapeutic effects and vulnerability to their harmful effects.

National Longitudinal Study of the Neurodevelopmental Consequences of Substance Use

Photo of a group of teens

By Nora Volkow (Director, NIDA), George Koob (Director, NIAAA), Alan Guttmacher (Director, NICHD), and Bob Croyle (Director, Divison of Cancer Control and Population Sciences, NCI)

Dr. Joni Rutter Q&A: How Basic Science Is Tackling Addiction

One of NIDA’s goals is to try to understand the individual differences that contribute to whether or not someone who takes a drug will become addicted to it. Dr. Rutter’s research focuses on three types of differences: Environmental, developmental, and genetic and epigenetic.

National RX Drug Abuse Summit

Abuse of prescription opioids, stimulants, and other psychotherapeutic medications presents unique challenges. On the one hand, these drugs can produce serious harm (even death) when not taken as prescribed; on the other, they are powerful clinical allies that can be life saving.  Thus, the approach we take and the messages we convey to minimize harm need to be nuanced and multipronged.

Páginas

Take the IQ Challenge en Español!